NeuBase Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Cover
- Document and Entity Information
Financial Statements
Notes to Financial Statements
Accounting Policies
- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
Notes Tables
Notes Details

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

ACCOUNTS PAYABLE AND ACCRUED EXPENSES	6 Months Ended
Mar. 31, 2016
Payables and Accruals [Abstract]
ACCOUNTS PAYABLE AND ACCRUED EXPENSES	NOTE 4 ACCOUNTS PAYABLE AND ACCRUED EXPENSES During the three and six month periods ended March 31, 2016, the Company realized a gain of $710,264 related to the settlement of an accounts payable balance.

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

6 Months Ended

Mar. 31, 2016

Payables and Accruals [Abstract]

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

NOTE 4 ACCOUNTS PAYABLE AND ACCRUED EXPENSES

During the three and six month periods ended March 31, 2016, the Company realized a gain of $710,264 related to the settlement of an accounts payable balance.